EUVIMEDEUVIMED entdecken
Leserbrief

Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”

Jeremie Calais, RE-LuPSMA investigators

Journal of Nuclear Medicine · 29.10.2026 · jnumed.126.274063

DOI: 10.2967/jnumed.126.274063 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 29.10.2026. Verfasst von Jeremie Calais und 1 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

REPLY: We thank Dr. Çınar for the interest in our RE-LuPSMA protocol ([1][1]) and for raising the question of biologic heterogeneity at the time of rechallenge. First, a clarification on eligibility. RE-LuPSMA enrolls patients who responded to a prior course of [177Lu]Lu-PSMA-617 and progressed

Zitieren

APA

Calais, J., & RE-LuPSMA investigators (2026). Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”. Journal of Nuclear Medicine, jnumed.126.274063. https://doi.org/10.2967/jnumed.126.274063

Vancouver

Calais J, RE-LuPSMA investigators. Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”. Journal of Nuclear Medicine. 2026:jnumed.126.274063. doi:10.2967/jnumed.126.274063

BibTeX
@article{Calais2026,
  author = {Calais, Jeremie and RE-LuPSMA investigators, RE-LuPSMA investigators},
  title = {Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  pages = {jnumed.126.274063},
  doi = {10.2967/jnumed.126.274063}
}
Kostenlos starten →